Regentys Overview
- Founded
-
2013

- Status
-
Acquired/Merged
- Employees
-
4

- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$15M
Regentys General Information
Description
Manufacturer of medical devices created to treat gastrointestinal (GI) disorders. The company manufactures a porcine-derived biological material which acts as a catalyst to stimulate the body to grow new, healthy tissue in place of diseased or damaged tissue and it mainly focuses on tissue-engineered treatment for Inflammatory Bowel Disease (IBD), enabling patients to recover gastrointestinal (GI) disorders.
Contact Information
Website
www.regentys.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Parent Company
Primary Office
- 6135 Northwest 167th Street
- Suite E15
- Hialeah, FL 33015
- United States
+1 (844) 000-0000
Regentys Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Merger/Acquisition | 07-Jan-2019 | $15M | 00.00 | 000.00 | Completed | Generating Revenue |
2. Early Stage VC (Series A) | 07-Nov-2016 | 00.000 | 00.00 | Completed | Generating Revenue | |
1. Accelerator/Incubator | 31-Oct-2014 | $250K | $250K | 000 | Completed | Generating Revenue |
Regentys Patents
Regentys Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2017313207-A1 | Extracellular matrix for tissue reconstruction of mucosal tissue | Inactive | 19-Aug-2016 | 00000000000 | |
CA-3034251-A1 | Extracellular matrix for tissue reconstruction of mucosal tissue | Pending | 19-Aug-2016 | 00000000000 | |
EP-3500193-A4 | Extracellular matrix for tissue reconstruction of mucosal tissue | Pending | 19-Aug-2016 | 00000000000 | 0 |
EP-3500193-A1 | Extracellular matrix for tissue reconstruction of mucosal tissue | Pending | 19-Aug-2016 | 00000000000 | |
US-20190184060-A1 | Extracellular matrix for tissue reconstruction of mucosal tissue | Inactive | 19-Aug-2016 | A61L27/3633 |
Regentys Executive Team (6)
Regentys Board Members (6)
Name | Representing | Role | Since |
---|---|---|---|
Darren Sloniger | Self | Board Member | 000 0000 |
Hal Wrigley | Regentys | Board Member | 000 0000 |
Michael Phalen | Self | Board Member | 000 0000 |
Reginald Hardy | Self | Board Member | 000 0000 |
Sergio Gonzalez JD | Regentys | Board Member | 000 0000 |
Regentys Signals
Regentys Former Investors (1)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
43North | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |